Recent research suggests a possible increased risk of serious eye conditions, such as non-arteritic anterior ischaemic optic ...

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...

A popular drug used for diabetes and weight loss may also help protect the brain. That’s the key message from a new study ...

Semaglutide is the active ingredient in the weight loss medication Wegovy and the diabetes drugs Ozempic and Rybelsus, which ...

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and ...

A study has found that prescribing semaglutide in everyday clinical settings led to modest but meaningful improvements in cardiovascular risk alongside a rise in non-drug healthcare costs. The study, ...

NAION is the second most frequent cause of vision loss due to optic nerve damage, with advanced age and long-standing type 2 ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Semaglutide, a GLP-1 receptor agonist, has already shown benefits for weight loss and cardiovascular health. This new study adds to growing evidence that the drug’s effects may extend to ...

In this cohort study of adults prescribed semaglutide, initiation was associated with reductions in weight and cardiovascular risk ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.